imatinib mesylate has been researched along with Bright Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akizawa, T; Iyoda, M; Kawaguchi, M; Shibata, T; Yamaoka, T | 1 |
| Harada, M; Hirakata, H; Igawa, T; Masutani, K; Miyake, K; Nakashima, H; Niiro, H; Sadanaga, A; Shimizu, S; Sugiyama, N | 1 |
2 other study(ies) available for imatinib mesylate and Bright Disease
| Article | Year |
|---|---|
Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis.
Topics: Animals; Basement Membrane; Benzamides; Creatinine; Glomerulonephritis; Imatinib Mesylate; Kidney Glomerulus; Macrophages; Piperazines; Protective Agents; Proteinuria; Pyrimidines; Rats; Rats, Wistar; Treatment Outcome; Urea | 2009 |
Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice.
Topics: Animals; Antineoplastic Agents; Autoantibodies; Benzamides; Blood Urea Nitrogen; CD4-Positive T-Lymphocytes; Creatinine; DNA; Female; Glomerulonephritis; Imatinib Mesylate; Immunoglobulin G; Interferon-gamma; Lupus Nephritis; Lymphatic Diseases; Mice; Mice, Inbred MRL lpr; Piperazines; Platelet-Derived Growth Factor; Proteinuria; Pyrimidines; Salivary Glands; Severity of Illness Index; Spleen; Splenomegaly; Survival Analysis | 2005 |